Inclusion Criteria:

- Patients with histologically confirmed diagnosis of CRC

- Measurable metastatic disease to the liver in proven disease progression (according
to RECIST criteria) at baseline (within 4 weeks prior to study entry), with at least
one lesion > 2cm considered appropriate for DCE-US examination

- Previously exposed to at least, irinotecan, oxaliplatin and a fluoropyrimidine, all 3
administered at optimal doses, over one or two chemotherapy (CT) lines for metastatic
disease with a clear resistance to these drugs. Previous exposure to bevacizumab
and/or anti-EGFR monoclonal antibody is allowed.

- Age ≥18 years; Performance Status (PS) 0-2 and life expectancy > 3 months.

- Adequate biological functions: Neutrophils ≥ 1.5 x 109/L; Platelets ≥ 100 x 109/L;
Hemoglobin > 9 g/dl; Creatinine clearance > 30 ml/min (cockcroft & Gault formula).
Serum bilirubin < 1,5 x the upper normal limit (UNL) and AST/ALT < 5 x UNL.

- Signed written informed consent

- Female patients with childbearing potential (<2 years after last menstruation) and
male must use effective means of contraception during the study treatment and at
least 6 months after the last study drug administration.